Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Difelikefalin for Pruritus in Chinese Hemodialysis Patients
NCT05885737Phase 3Completed
- Sponsor
- CSL Vifor
- Start
- May 2023
- Primary completion
- Sep 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of difelikefalin in uremic pruritus (3 arms), sponsored by CSL Vifor. Primary endpoint: Change From Baseline in the Weekly Mean of the Daily 24-hour WI-NRS Score at Week 4. Started May 2023; status: completed.
02
Drugs
difelikefalin
03
Conditions
uremic pruritus
Beyond the preview
Go deeper on NCT05885737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05885737.